Shots:
- Medtronic has announced its intent to acquire SPR Therapeutics for an upfront payment of ~$650M, aiming to expand its neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) tech for chronic pain management
- Acquisition will add SPR’s FDA-cleared SPRINT PNS System to Medtronic’s pain management portfolio, which showed over 71% pts experienced significant pain relief &/or QoL improvement from Real-world retrospective data (n > 6,100) following 60-day percutaneous PNS treatment
- The deal is expected to close in the first half of Medtronic’s FY’27, subject to regulatory approvals and customary closing conditions
Ref: PRnewswire | Image: SPR Therapeutics | Press Release
Related News: Pulnovo Raises $100M Led by Medtronic to Advance PADN System for Pulmonary Hypertension
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
